Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Genetic counseling
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Genetic counseling

1 evidence topic · 1 source

Genetic counseling and family planning

“visit a genetic counselor who can discuss disease inheritance and help with family planning, career choices” (opens the source at this quote in a new tab)